Drug Trial Radar · NCT01869491
Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
Last checked: Nov 20, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,107
Actual
Start
Jun 5, 2013
Primary completion
May 2014
Study completion May 2014
Sponsor
- Lead sponsor
- Reckitt Benckiser Healthcare (UK) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).
Conditions
- Gastroesophageal Reflux Disease
- Dyspepsia
Interventions
Compound Sodium Alginate Double Action Chewable TabletsDrug
2 tablets four times daily
Matching placebo tabletsDrug
2 tablets four times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Reflux Disease Questionnaire (RDQ) Scores for the GERD DimensionTime frame: 7 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
RB Investigational Sites
Beijing, China
RB Investigational Sites
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.